Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 31 peer-reviewed journal articles Updated
Medical Oncology · Malignant neoplasm of upper-outer quadrant of female breast

Life After Treatment: Surveillance and Survivorship

At a Glance

After breast cancer treatment, scheduled exams and mammograms are the main ways to monitor health; routine scans and tumor-marker blood tests usually do not help when you have no symptoms. Report new lumps or persistent symptoms promptly and address treatment side effects with your care team.

Transitioning from active treatment to survivorship is often a time of mixed emotions. While you may feel relief that surgery and radiation are behind you, it is common to feel a new kind of “scan anxiety” or hyper-vigilance about every new ache or pain. Your follow-up care is designed to balance the need for careful monitoring with the goal of helping you return to a full, active life without unnecessary medical interventions [1][2].

The Surveillance Roadmap

Once active treatment is complete, your care shifts from “fighting” the cancer to “surveillance”—the process of looking for any signs of local recurrence or new primary cancers [1].

  • Clinical Exams: Standard guidelines from ASCO (American Society of Clinical Oncology) and the NCCN recommend a physical exam and medical history every 3 to 6 months for the first three years, every 6 to 12 months for the next two years, and then annually [1][2].
  • Imaging: After breast-conserving surgery, surveillance includes your treated and contralateral breasts; the first post-treatment mammogram is commonly obtained 6–12 months after surgery/radiation, then annually. After a unilateral mastectomy, routine mammography is for your remaining breast [3].
  • MRI: Supplemental screening with an MRI is not standard for everyone; it is typically reserved for survivors with a high genetic risk (such as a BRCA mutation) or a calculated lifetime risk of a new breast cancer over 20% [4][5].

Why “Less is More” with Body Scans

It may seem counterintuitive, but for survivors who do not have symptoms, more testing does not lead to better outcomes. Leading oncology organizations do not recommend routine body scans (such as PET/CT, CT, or bone scans) or blood tests for “tumor markers” (like CA 15-3 or CEA) for asymptomatic patients [1][P-152][P-153].

Research has consistently shown that these tests do not improve survival rates or quality of life for survivors [1][2]. Instead, they often lead to:

  • False Positives: Scans can find “spots” that are actually benign (non-cancerous), leading to unnecessary anxiety, more scans, and invasive biopsies [6][7].
  • Lead-Time Bias: Finding a distant recurrence a few months earlier via a scan—before it causes symptoms—has not been proven to change the eventual outcome [1].

When to Call the Doctor: Reporting Symptoms

The most effective way to monitor for recurrence is for you to be aware of your body. However, you must differentiate emergency symptoms from routine concerns.

Emergency Symptoms (Seek immediate/urgent care):

  • Sudden, severe shortness of breath or sudden chest pain [8].
  • Sudden neurological changes, new seizures, severe headache, or new vision changes [9].

Report these symptoms promptly (Do not wait for your next appointment):

  • New Lumps: A new or persistent palpable mass or thickening in the breast, chest wall, armpit, or near the collarbone [10][11].
  • Persistent Bone Pain: Focal pain (in one specific spot like the back, hip, or rib) that is constant, hurts at night, or is not related to an injury [12].
  • Respiratory Changes: A new, persistent cough [8].
  • Systemic Symptoms: Unexplained weight loss or a persistent feeling of being unwell [9].

Navigating Endocrine Therapy Side Effects

As covered on the systemic therapy page, you may be taking hormone-blocking pills for 5 to 10 years. While these drugs are highly effective, their side effects are common and can impact your daily life [13][14].

  • Joint and Muscle Pain (Arthralgia): Often caused by Aromatase Inhibitors. Movement is medicine; studies show that individualized physical activity and yoga can significantly reduce this pain [15][16]. In some cases, the medication duloxetine may be prescribed to help [17].
  • Hot Flashes: Non-hormonal options are the gold standard for survivors. Certain antidepressants (like venlafaxine) or acupuncture have been shown to reduce the severity of hot flashes [18][19]. Important: If you take tamoxifen, always check for drug interactions before starting an antidepressant. Strong inhibitors like paroxetine or fluoxetine can reduce the effectiveness of tamoxifen; venlafaxine is often considered a safer alternative, but medication selection must be guided by your clinician.
  • Genitourinary Syndrome of Menopause (GSM): This includes vaginal dryness and discomfort. First-line treatments include non-hormonal moisturizers (used regularly) and lubricants (used for activity) [17][16]. If symptoms are severe, you and your oncologist may discuss low-dose vaginal estrogen, though this requires careful shared decision-making, especially if you are taking an Aromatase Inhibitor. Persistent vaginal bleeding always requires evaluation [20][21].

Long-term Health Monitoring

Because cancer treatments can affect other systems in your body, your survivorship plan includes monitoring your “whole-body” health.

  • Bone Health: Aromatase inhibitors and ovarian suppression can accelerate bone loss, whereas tamoxifen has different bone effects depending on your menopausal status. Your doctor will monitor you with DXA scans (bone density tests) and may recommend weight-bearing exercise to prevent osteoporosis [22][23]. Do not start supplements or bone drugs without consulting your treating team.
  • Cardiovascular Health: If your treatment included certain chemotherapies (anthracyclines) or HER2-targeted drugs, your heart function may be monitored with periodic echocardiograms [24][25].
  • Emotional & Practical Wellbeing: Address sexual health, mental-health support, work/financial concerns, and fatigue with your team. Survivorship counseling or a patient navigator can help manage these quality-of-life needs.

Lymphedema and Physical Recovery

As noted in your surgical discussion, the risk of lymphedema (arm swelling) is a lifelong consideration, especially if you had lymph nodes removed or received radiation to the armpit area [26].

Surveillance for lymphedema involves serial assessments—comparing measurements of your arms over time to catch swelling before it is visible to the eye [26][27]. If lymphedema is identified, Complete Decongestive Therapy (CDT)—which includes specialized massage, compression garments, and specific exercises—is the standard of care to manage the fluid and prevent it from worsening [28][29]. Physical rehabilitation is not just for lymphedema; it can also help restore your shoulder’s range of motion and overall strength following surgery [30][31].

Common questions in this guide

How often should I have follow-up visits after breast cancer treatment?
Most guidelines recommend a history and physical exam every 3 to 6 months during the first 3 years, every 6 to 12 months for the next 2 years, and then once a year. Mammograms are typically done 6 to 12 months after surgery and radiation, then annually; after a unilateral mastectomy, mammography is used for the remaining breast.
Do I need routine PET or CT scans after breast cancer treatment if I feel well?
Usually not. For people without symptoms, routine PET/CT, CT, bone scans, and tumor-marker blood tests have not been shown to improve survival or quality of life and can lead to false alarms and unnecessary procedures.
What symptoms should I report between appointments?
Contact your care team promptly about a new or persistent lump or thickening in the breast, chest wall, armpit, or near the collarbone; focal bone pain that is constant or worse at night; a persistent cough; unexplained weight loss; or feeling persistently unwell. Sudden severe shortness of breath, chest pain, new neurological changes, seizures, severe headache, or new vision changes require urgent or emergency care.
Will I need an MRI after breast cancer treatment?
MRI is not routine for every survivor. It is usually considered when someone has a BRCA mutation or another high genetic risk, such as a calculated lifetime risk above 20%, and your clinician can determine whether it is appropriate.
How can endocrine therapy side effects be managed?
Exercise and yoga may help joint and muscle pain from aromatase inhibitors, and a clinician may consider duloxetine when needed. Nonhormonal approaches, such as certain medicines or acupuncture, can help hot flashes; if you take tamoxifen, ask before starting an antidepressant because some can reduce its effectiveness.
How will my bone health be monitored after breast cancer treatment?
Aromatase inhibitors and ovarian suppression can speed bone loss, so your clinician may use DXA bone-density scans and recommend weight-bearing exercise. Do not start supplements or bone medicines without discussing them with your treating team.
What happens if I develop lymphedema after breast cancer surgery?
Lymphedema causes swelling, often in an arm, and risk is higher after lymph-node removal or radiation near the armpit. Regular arm measurements can detect changes early; treatment may include specialized massage, compression garments, and exercises through Complete Decongestive Therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific risk and surgical history, how often will we do a clinical breast exam and which imaging tests do I need?
  2. 2.Since I am taking [Tamoxifen/Aromatase Inhibitor], what is our individualized plan for monitoring my bone density?
  3. 3.Can you recommend a physical therapist or lymphedema specialist to help me set up a long-term exercise and monitoring routine?
  4. 4.If I experience side effects like joint pain or vaginal dryness, what is our 'step-up' plan if first-line remedies don't work?
  5. 5.What symptoms warrant an immediate trip to the emergency room versus a prompt call to your office?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (31)
  1. 1

    American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

    Runowicz CD, Leach CR, Henry NL, et al.

    CA: a cancer journal for clinicians 2016; (66(1)):43-73 doi:10.3322/caac.21319.

    PMID: 26641959
  2. 2

    American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

    Runowicz CD, Leach CR, Henry NL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(6)):611-35 doi:10.1200/JCO.2015.64.3809.

    PMID: 26644543
  3. 3

    Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement.

    Freedman RA, Minami CA, Winer EP, et al.

    JAMA oncology 2021; (7(4)):609-615 doi:10.1001/jamaoncol.2020.7582.

    PMID: 33507222
  4. 4

    Identification and management of women with a family history of breast cancer: Practical guide for clinicians.

    Heisey R, Carroll JC

    Canadian family physician Medecin de famille canadien 2016; (62(10)):799-803.

    PMID: 27737975
  5. 5

    LONG-TERM SURVIVAL EFFECTS OF PREOPERATIVE BREAST MRI IN PATIENTS WITH BREAST-CONSERVING SURGERY.

    Ilgun AS, Sarsenov D, Alco G, et al.

    Acta clinica Croatica 2022; (61(1)):30-37 doi:10.20471/acc.2022.61.01.04.

    PMID: 36398075
  6. 6

    Impact of Preoperative Extramammary Findings in Patients with Newly Diagnosed Breast Cancer.

    Gleckler L, Roy N, Bernstein M, et al.

    Journal of the American College of Surgeons 2023; (236(5)):1047-1053 doi:10.1097/XCS.0000000000000605.

    PMID: 36719075
  7. 7

    Frequency and Clinical Significance of Extramammary Findings on Breast Magnetic Resonance Imaging.

    Phadke S, Thomas A, Yang L, et al.

    Clinical breast cancer 2016; (16(5)):424-429 doi:10.1016/j.clbc.2015.08.003.

    PMID: 26403074
  8. 8

    Laryngeal metastases from breast cancer: A rare clinical entity.

    Kumar R, Kumar S, Gogia A, et al.

    Current problems in cancer 2019; (43(2)):130-134 doi:10.1016/j.currproblcancer.2018.07.010.

    PMID: 30119910
  9. 9

    Early re-staging and molecular subtype shift surveillance of locally recurrent or metastatic breast cancer: A new PET/CT integrated precise algorithm.

    Guo W, Hao B, Luo N, et al.

    Cancer letters 2018; (418()):221-229 doi:10.1016/j.canlet.2018.01.019.

    PMID: 29337111
  10. 10

    Monitoring for Breast Cancer Recurrence Following Goldilocks Breast Reconstruction.

    Wang J, Ghanouni A, Losken A, Thompson P

    Annals of plastic surgery 2024; (92(6S Suppl 4)):S432-S436 doi:10.1097/SAP.0000000000003952.

    PMID: 38857009
  11. 11

    Value of ultrasound-guided fine needle aspiration in diagnosing axillary lymph node recurrence after breast cancer surgery.

    Park VY, Kim EK, Moon HJ, et al.

    American journal of surgery 2018; (216(5)):969-973 doi:10.1016/j.amjsurg.2018.04.012.

    PMID: 29709272
  12. 12

    Not All Bone Lesions After Breast Cancer Treatment Indicate Metastasis: A Case Report and Review of the Literature.

    Kaakoua M, Mohamed Amine A, Ebbadi N, et al.

    Cureus 2025; (17(11)):e96191 doi:10.7759/cureus.96191.

    PMID: 41362513
  13. 13

    Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects.

    Rojas K, Spring LM, O'Riordan L, Weiss A

    Annals of surgical oncology 2023; (30(10)):5951-5961 doi:10.1245/s10434-023-13907-4.

    PMID: 37495843
  14. 14

    Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study.

    Moskalewicz A, Di Tomaso A, Kachura JJ, et al.

    Current oncology (Toronto, Ont.) 2022; (29(3)):1813-1827 doi:10.3390/curroncol29030149.

    PMID: 35323349
  15. 15

    Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy.

    Di Meglio A, Soldato D, Presti D, Vaz-Luis I

    Current opinion in oncology 2021; (33(6)):553-573 doi:10.1097/CCO.0000000000000781.

    PMID: 34456250
  16. 16

    Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review.

    Dos Santos BS, Bordignon C, Rosa DD

    Current oncology reports 2021; (23(6)):63 doi:10.1007/s11912-021-01055-5.

    PMID: 33852059
  17. 17

    Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines.

    Hall LH, King NV, Graham CD, et al.

    Journal of cancer survivorship : research and practice 2022; (16(6)):1296-1338 doi:10.1007/s11764-021-01114-7.

    PMID: 34664199
  18. 18

    Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials.

    Lu W, Giobbie-Hurder A, Tanasijevic A, et al.

    Cancer 2024; (130(18)):3219-3228 doi:10.1002/cncr.35374.

    PMID: 38924035
  19. 19

    Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.

    Vrselja A, Latifi A, Baber RJ, et al.

    Lancet (London, England) 2022; (400(10364)):1704-1711 doi:10.1016/S0140-6736(22)01977-8.

    PMID: 36366886
  20. 20

    Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.

    Cold S, Cold F, Jensen MB, et al.

    Journal of the National Cancer Institute 2022; (114(10)):1347-1354 doi:10.1093/jnci/djac112.

    PMID: 35854422
  21. 21

    Genitourinary syndrome of menopause in women with cancer - a narrative review.

    Ryan HM, Brennan DJ

    Maturitas 2026; (211()):109004 doi:10.1016/j.maturitas.2026.109004.

    PMID: 42224847
  22. 22

    Primary Care of Breast Cancer Survivors.

    Zoberi K, Tucker J

    American family physician 2019; (99(6)):370-375.

    PMID: 30874405
  23. 23

    Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review.

    Gomes B, Vale N

    Current oncology (Toronto, Ont.) 2025; (32(6)) doi:10.3390/curroncol32060305.

    PMID: 40558248
  24. 24

    Cardiovascular care in adult cancer survivorship post-therapy: a cross-sectional analysis of clinical practice guidelines.

    Ayoson J, Schneider N, Müller N, et al.

    Cardio-oncology (London, England) 2026; (12(1)).

    PMID: 42057201
  25. 25

    Cancer survivor late-effects, chronic health problems after cancer treatment: what's the evidence from population and registry data and where are the gaps?

    Faithfull S, Greenfield D

    Current opinion in supportive and palliative care 2024; (18(1)):55-64 doi:10.1097/SPC.0000000000000692.

    PMID: 38170192
  26. 26

    Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments.

    Gillespie TC, Sayegh HE, Brunelle CL, et al.

    Gland surgery 2018; (7(4)):379-403 doi:10.21037/gs.2017.11.04.

    PMID: 30175055
  27. 27

    Effects of Early Preventive Interventions on Breast Cancer-Related Lymphedema: A Meta-Analysis and Systematic Review.

    Wu Y, Zhou Z, Li J, et al.

    Cancer nursing 2026; doi:10.1097/NCC.0000000000001557.

    PMID: 41817405
  28. 28

    Breast Cancer-Related Lymphedema: Recent Updates on Diagnosis, Severity and Available Treatments.

    Pappalardo M, Starnoni M, Franceschini G, et al.

    Journal of personalized medicine 2021; (11(5)) doi:10.3390/jpm11050402.

    PMID: 34065795
  29. 29

    The Effect of Exercise on Reducing Lymphedema Severity in Breast Cancer Survivors.

    Lian Y, Sandhu S, Asefa Y, Gupta A

    Cancers 2024; (16(7)) doi:10.3390/cancers16071367.

    PMID: 38611045
  30. 30

    Women's Rehabilitation Experiences Following Breast Cancer Surgery.

    Reigle BS, Zhang B

    Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses 2018; (43(4)):195-200 doi:10.1097/rnj.0000000000000168.

    PMID: 29957696
  31. 31

    Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.

    de Paulo TRS, Winters-Stone KM, Viezel J, et al.

    Disability and rehabilitation 2019; (41(18)):2175-2182 doi:10.1080/09638288.2018.1460877.

    PMID: 29644889

This page is for informational purposes only and does not constitute medical advice. Your oncology team should set your follow-up schedule and evaluate new symptoms or treatment side effects.

Get notified when new evidence is published on female breast upper-outer quadrant cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.